B. Bayer, G. Squibb, . Prof-myers-squibb, . Janssen, M. Siemens et al., Zarski consults for and is on the speakers' bureau of Gilead Pol was a speaker for He received grants from Bristol-Myers Squibb, Gilead, Roche, and MSD. He consults for Gilead Alric consults for and received grants from Bristol-Myers Squibb, MSD, and Gilead. He received grants from Roche and Janssen. Dr. Bourliere consults for and advises, Declaration of interests: Prof. Ganne-Carrié and Dr. Nahon received honoraria from Di Martino consults for and advises Gilead, MSD, Janssen and Bristol-Myers Squibb. Dr. Bacq has served as a speaker for Roche, Gilead or Bristol-Myers Squibb. Dr Roudot-Thoraval is an advisor for Roche, Gilead and AbbVie, and served as speaker for Roche

T. Stroffolini, I. Zagni, and F. Donato, PhD Email: nathalie.ganne@jvr.aphp.fr REFERENCES 1. El-Serag HB. Epidemiology of viral hepatitis and hepatocellular carcinoma Hepatocellular carcinoma in cirrhosis: incidence and risk factors, Correspondence: Nathalie Ganne-Carrié, MD, pp.1264-1273, 2004.

A. Lok, L. Seeff, T. Morgan, A. Di-bisceglie, R. Sterling et al., Incidence of Hepatocellular Carcinoma and Associated Risk Factors in Hepatitis C-Related Advanced Liver Disease, Gastroenterology, vol.136, issue.1, pp.138-148, 2009.
DOI : 10.1053/j.gastro.2008.09.014

J. Trinchet, V. Bourcier, C. Chaffaut, A. Ahmed, M. Allam et al., Complications and competing risks of death in compensated viral cirrhosis (ANRS CO12 CirVir prospective cohort), Hepatology, vol.55, issue.2 Suppl 1
DOI : 10.1002/hep.27743
URL : https://hal.archives-ouvertes.fr/hal-01201948

J. Bruix and M. Sherman, Management of hepatocellular carcinoma, Hepatology, vol.35, issue.5, pp.1208-1236, 2005.
DOI : 10.1002/hep.20933

F. Degos, C. Christidis, N. Ganne-carrie, J. Farmachidi, C. Degott et al., Hepatitis C virus related cirrhosis: time to occurrence of hepatocellular carcinoma and death, Gut, vol.47, issue.1, pp.131-136, 2000.
DOI : 10.1136/gut.47.1.131

J. Trinchet, Risk factors for hepatocellular carcinoma in patients with alcoholic or viral C cirrhosis, Clin Gastroenterol Hepatol, vol.4, pp.1062-1068, 2006.

R. Morgan, B. Baack, B. Smith, A. Yartel, M. Pitasi et al., Eradication of Hepatitis C Virus Infection and the Development of Hepatocellular Carcinoma, Annals of Internal Medicine, vol.158, issue.5_Part_1, pp.329-337, 2013.
DOI : 10.7326/0003-4819-158-5-201303050-00005

C. Drinking, G. Hepatocellular-carcinoma-risk-nkontchou, E. Cosson, M. Aout, A. Mahmoudi et al., Impact of metformin on the prognosis of cirrhosis induced by viral hepatitis C in diabetic patients Statins Are Associated With a Decreased Risk of Decompensation and Death in Veterans With Hepatitis C-Related Compensated Cirrhosis, Hepatology J Clin Endocrinol Metab Gastroenterology, vol.4696150, issue.12, pp.430-4352601, 2007.

K. Alberti, P. Zimmet, and J. Shaw, The metabolic syndrome???a new worldwide definition, The Lancet, vol.366, issue.9491, pp.1059-1062, 2005.
DOI : 10.1016/S0140-6736(05)67402-8

J. Bruix and M. Sherman, Management of hepatocellular carcinoma: An update, Hepatology, vol.10, issue.Suppl 1, pp.1020-1022, 2011.
DOI : 10.1002/hep.24199

S. Bruno, T. Stroffolini, M. Colombo, S. Bollani, L. Benvegnu et al., Sustained virological response to interferon-?? is associated with improved outcome in HCV-related cirrhosis: A retrospective study, Hepatology, vol.130, issue.3, pp.579-587, 2007.
DOI : 10.1002/hep.21492

D. Marco, V. Calvaruso, V. Ferraro, D. Bavetta, M. Cabibbo et al., Effects of Viral Eradication in Patients with HCV and Cirrhosis Differ With Stage of Portal Hypertension, Gastroenterology, 2016.

I. Martinez, Prospective analysis of risk factors for hepatocellular carcinoma in patients with liver cirrhosis, Hepatology, vol.37, pp.520-527, 2003.

H. Yang, M. Yuen, H. Chan, K. Han, P. Chen et al., Risk estimation for hepatocellular carcinoma in chronic hepatitis B (REACH-B): development and validation of a predictive score, The Lancet Oncology, vol.12, issue.6, pp.568-574, 2011.
DOI : 10.1016/S1470-2045(11)70077-8

V. Wong, S. Chan, F. Mo, T. Chan, H. Loong et al., Clinical scoring system to predict hepatocellular carcinoma in chronic hepatitis B carriers Incidence and predictors of hepatocellular carcinoma in Caucasian chronic hepatitis B patients receiving entecavir or tenofovir, J Clin Oncol J Hepatol, vol.2862, issue.25, pp.1660-1665363, 2010.

M. Abu-amara, O. Cerocchi, G. Malhi, S. Sharma, C. Yim et al., The applicability of hepatocellular carcinoma risk prediction scores in a North American patient population with chronic hepatitis B infection Clinicalguide risk prediction of hepatocellular carcinoma development in chronic hepatitis C patients after interferon-based therapy Development and validation of a clinical scoring system for predicting risk of HCC in asymptomatic individuals seropositive for anti-HCV antibodies A new laboratory-based algorithm to predict development of hepatocellular carcinoma in patients with hepatitis C and cirrhosis, Gut Br J Cancer PLoS One Gastroenterology, vol.271099146, issue.28, pp.2481-24881249, 2013.

A. Rojo, Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis, Jama, vol.308, pp.2584-2593, 2012.

C. Hôpital and N. , Amiens (D. Capron); CHU Angers (P.Calès); Hôpital Saint-Joseph, Marseille (M.BourlièreJ.P.Bronowicki

C. Pontchaillou and R. , Guyader); CH Pays d'Aix, Aix-en-Provence (C.Wartelle)

C. Purpan, (. J. Toulouse, and L. Péron, Alric)

/. Funding and . Support, This study was sponsored by the ANRS (France REcherche Nord & sud Sida-hiv Hépatites: FRENSH)

A. Nahon, . Bourcier, . Cagnot, R. Layese, . Ganne-carrié et al., Study supervision Roudot-Thoraval Declaration of interests: Prof. Ganne-Carrié and Dr. Nahon received honoraria from Bayer Zarski consults for and is on the speakers' bureau of Gilead, Bristol- Myers Squibb, Janssen, Siemens and MSD. He consults for AbbVie. Prof. Pol was a speaker for He received grants from Bristol-Myers Squibb, Gilead, Roche, and MSD. He consults for Gilead Alric consults for and received grants from Bristol-Myers Squibb, MSD, and Gilead. He received grants from Roche and Janssen. Dr. Bourliere consults for and advises, Prof. Di Martino consults for and advises Gilead,MSD, Janssen and Bristol-Myers Squibb. Dr. Bacq has served as a speaker for Roche, Gilead or Bristol-Myers Squibb. Dr. Roudot-Thoraval is an advisor for Roche, Gilead and AbbVie, and served as speaker for Roche